ReviewVascular health and risk management2010
Advances in the treatment of Raynaud's phenomenon.
Review in Vascular health and risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- A systematic review of botulinum toxin as a treatment for Raynaud's disease secondary to scleroderma.Clinical rheumatology · 2025Pooled it
- Pooled it
- Calcium channel blockers for primary and secondary Raynaud's phenomenon.The Cochrane database of systematic reviews · 2017Pooled it
- Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population.Rheumatology international · 2013Pooled it
- Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT).Clinical drug investigation · 2018Trial
- Acupuncture in subjects with cold hands sensation: study protocol for a randomized controlled trial.Trials · 2014Trial
- Trial
- Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.Vascular specialist international · 2024Review
- Blood vessels in a dish: the evolution, challenges, and potential of vascularized tissues and organoids.Frontiers in cardiovascular medicine · 2024Review
- Iloprost for the treatment of frostbite: a scoping review.International journal of circumpolar health · 2023Article
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.The Cochrane database of systematic reviews · 2023Review
- Raynaud's Phenomenon with Focus on Systemic Sclerosis.Journal of clinical medicine · 2022Review
- Review
- The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon: A Case Series.Cureus · 2020Article
- Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.Arthritis care & research · 2020Article
- Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.Clinical rheumatology · 2019Article
- The mechanism of botulinum A on Raynaud syndrome.Drug design, development and therapy · 2018Article
- Effects of cold sensitivity in the extremities on circulating adiponectin levels and metabolic syndrome in women.BMC complementary and alternative medicine · 2017Article
- Botulinum Toxin Off-Label Use in Dermatology: A Review.Skin appendage disorders · 2017Review
- Difficulties in diagnosis and treatment of severe secondary Raynaud's phenomenon in a Cameroonian woman: a case report.Journal of medical case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raynaud's phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.